hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.
about
Hepatocyte nuclear factor 1 regulates the expression of the organic cation transporter 1 via binding to an evolutionary conserved region in intron 1 of the OCT1 geneThe pharmacogenetics of imanitib.SLC22A1-ABCB1 haplotype profiles predict imatinib pharmacokinetics in Asian patients with chronic myeloid leukemia.Organic Cation Transporter 1 (OCT1) mRNA expression in hepatocellular carcinoma as a biomarker for sorafenib treatmentWhole-genome studies identify solute carrier transporters in cellular susceptibility to paclitaxel.Cellular uptake of imatinib into leukemic cells is independent of human organic cation transporter 1 (OCT1).Mechanisms of resistance to BCR-ABL kinase inhibitors.Predicting the response of CML patients to tyrosine kinase inhibitor therapy.Selection of therapy: rational decisions based on molecular events.OCT1 and imatinib transport in CML: is it clinically relevant?Role of SLC22A1 polymorphic variants in drug disposition, therapeutic responses, and drug-drug interactions.Pharmacogenetics of tyrosine kinase inhibitors in gastrointestinal stromal tumor and chronic myeloid leukemia.hOCT1 gene expression predict for optimal response to Imatinib in Tunisian patients with chronic myeloid leukemia.Pharmacogenetics of drug transporters in modulating imatinib disposition and treatment outcomes in chronic myeloid leukemia & gastrointestinal stromal tumor patients.Significance of OCT1 Expression in Acute Myeloid Leukemia.Pharmacogenetics and Pharmacogenomics of Targeted Therapeutics in Chronic Myeloid Leukemia.Choosing the best second-line tyrosine kinase inhibitor in imatinib-resistant chronic myeloid leukemia patients harboring Bcr-Abl kinase domain mutations: how reliable is the IC₅₀?OCT-1 function varies with cell lineage but is not influenced by BCR-ABL.OCT-1 activity measurement provides a superior imatinib response predictor than screening for single-nucleotide polymorphisms of OCT-1.Pretherapeutic expression of the hOCT1 gene predicts a complete molecular response to imatinib mesylate in chronic-phase chronic myeloid leukemia.Imatinib Affects the Expression of SLC22A1 in a Non-Linear Concentration-Dependent Manner Within 24 Hours.OCT1 genetic variants are associated with long term outcomes in imatinib treated chronic myeloid leukemia patients.A common novel splice variant of SLC22A1 (OCT1) is associated with impaired responses to imatinib in patients with chronic myeloid leukaemia.OCT-1 as a determinant of response to antileukemic treatment.
P2860
Q28296115-F7010047-2377-4388-B704-FF37D0B8143DQ34469295-E49E3707-628B-4E7D-BCD4-B0F0A727267AQ34525644-15DAC946-B230-4CA8-8B8C-06F59E473221Q35922779-4C4F2868-2879-4EA5-B976-8AA6074FAD0EQ36035404-076D83DA-4BBC-4C9D-A402-ED0D2D2BADC4Q37598626-D5FE3C84-7A15-4A3A-87FF-BAE7B2EB9902Q37836923-7E31B0B2-B350-4D1F-B2FF-2D2573295C66Q37859303-824DFEC8-6CDA-4945-9784-321821AA0D7BQ37952910-F9424AAD-B469-43B9-8F54-D4A58D49FC5AQ38540022-EFDD2BFE-D289-48B3-858F-3FA983CE1CD6Q38622785-696321AA-F079-4724-A2E7-EFFC0F766E89Q38826494-920ED564-2D0E-4C06-B1CE-268393A93F2FQ38902116-E5CD4850-A9B3-4F80-A1A7-885630E0A517Q38996487-2BF8F739-0966-49A6-B4CF-6CE90EBE4387Q39062973-D194D8CE-D7A4-42AE-A48A-9D2E8EFA1F0BQ39429836-3227D355-7A08-468F-BE8A-6172B87CF667Q39516382-957B593A-4176-4BAE-A20C-0C988FACBD4EQ39640517-061ADE26-E5DA-46D9-A672-ECA0F8DC49EBQ42919961-C6B0F828-FA08-4BC1-808A-9EC7CA0186D5Q44161665-D36D0E79-1DB1-4E5E-AA21-86AE3AA13795Q52641813-09F57B0C-4C2E-4DBF-BBB9-78A21AB51676Q53083526-CFC9BF03-F518-4FFE-A896-3E0A55C1DC82Q54240000-6EDDC0D7-23B8-4E08-A879-51DBF52EE09CQ54610682-BBACE014-A8B9-4287-8E22-FA3D40D93EB7
P2860
hOCT1 transcript levels and single nucleotide polymorphisms as predictive factors for response to imatinib in chronic myeloid leukemia.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年学术文章
@wuu
2010年学术文章
@zh
2010年学术文章
@zh-cn
2010年学术文章
@zh-hans
2010年学术文章
@zh-my
2010年学术文章
@zh-sg
2010年學術文章
@yue
2010年學術文章
@zh-hant
name
hOCT1 transcript levels and si ...... b in chronic myeloid leukemia.
@en
hOCT1 transcript levels and si ...... b in chronic myeloid leukemia.
@nl
type
label
hOCT1 transcript levels and si ...... b in chronic myeloid leukemia.
@en
hOCT1 transcript levels and si ...... b in chronic myeloid leukemia.
@nl
prefLabel
hOCT1 transcript levels and si ...... b in chronic myeloid leukemia.
@en
hOCT1 transcript levels and si ...... b in chronic myeloid leukemia.
@nl
P2093
P2860
P921
P356
P1433
P1476
hOCT1 transcript levels and si ...... ib in chronic myeloid leukemia
@en
P2093
D Milojkovic
H de Lavallade
J F Apperley
J M Goldman
J S Khorashad
P2860
P2888
P304
P356
10.1038/LEU.2010.86
P577
2010-05-06T00:00:00Z
P5875
P6179
1046306855